Clinical trials: Ulcerative Colitis, Active
Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis), Inflamatory Bowel Disease
Physical Activity and Fitness in Pediatric Inflammatory Bowel Disease
Pediatric inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic condition associated not only with intestinal inflammation but also with reduced physical fitness, fatigue, impaired…
- Trial name
- PAFIT-IBD (NCT07484620)
- Testing
- Physical Activity Intervention
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad Complutense de Madrid
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active…
- Trial name
- Ametrine-2 (NCT06588855)
- Testing
- Afimkibart
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 350 people
- Sponsor
- Hoffmann-La Roche
Colitis, Ulcerative
An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with active ulcerative colitis, who are being…
- Trial name
- NCT00463151
- Testing
- rebamipide
- Where
- 5 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Ulcerative Colitis
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT02895100
- Testing
- PTG-100
- Where
- 98 sites in United States, Australia and 15 more
- Volunteers
- 98 people
- Sponsor
- Protagonist Therapeutics, Inc.
Ulcerative Colitis
A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy and safety of ozanimod compared with placebo in participants with ulcerative colitis (UC) in mainland China and Taiwan.
- Trial name
- NCT05644665
- Testing
- Ozanimod
- Where
- 51 sites in China, Taiwan
- Volunteers
- 131 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis, Inflammatory Bowel Diseases
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Trial name
- SKYLINE-UC (NCT07012395)
- Testing
- SPY001, SPY002, SPY003
- Where
- 276 sites in United States, Argentina and 33 more
- Volunteers
- 645 people
- Sponsor
- Spyre Therapeutics, Inc.
Ulcerative Colitis (UC)
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis.
- Trial name
- INT-210-II102 (NCT07692165)
- Testing
- INT-210 Capsule
- Where
- 15 sites in China
- Volunteers
- 24 people
- Sponsor
- Innatus Therapeutics (Shanghai) Co., Ltd.
Colitis, Ulcerative
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the accuracy of a subset of the length-109 probe set panel (a genetic test) in predicting response to golimumab treatment in participants with moderately to severely active ulcerative…
- Trial name
- NCT01988961
- Testing
- Golimumab
- Where
- 45 sites in United States, Belgium and 10 more
- Volunteers
- 103 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
The primary objective of this study is to evaluate the efficacy (as measured by induction of remission) of two dose levels (low and high) per age group (5 to <12 and 12 to ≤17 years) of budesonide rectal foam as compared to an…
- Trial name
- NCT05976802
- Testing
- High dose budesonide rectal foam, Low dose budesonide rectal foam
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Colitis, Ulcerative
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
This study is the first-time-in-patient trial of GSK1399686, a novel locally-acting anti-inflammatory compound, aimed at obtaining initial information on the tolerability, safety, pharmacokinetics (including concentrations in…
- Trial name
- NCT01036022
- Testing
- GSK1399686
- Where
- 26 sites in Belgium, Canada and 3 more
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Colitis, Ulcerative
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC…
- Trial name
- ICONIC-UC (NCT07196748)
- Testing
- Icotrokinra
- Where
- 402 sites in United States, Argentina and 26 more
- Volunteers
- 882 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC and to evaluate the efficacy of…
- Trial name
- CONCLUDE (NCT04985968)
- Testing
- Cobitolimod 250 mg, Cobitolimod 500 mg
- Where
- 203 sites in United States, Australia and 26 more
- Volunteers
- 171 people
- Sponsor
- InDex Pharmaceuticals
Ulcerative Colitis
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).
- Trial name
- UC (NCT02289417)
- Testing
- Apremilast
- Where
- 99 sites in United States, Australia and 12 more
- Volunteers
- 170 people
- Sponsor
- Amgen
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06764706
- Where
- 57 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AbbVie
Colitis, Ulcerative
Diet Intervention Treatment for Active Ulcerative Colitis
The purpose of this study is to determine if a sustainable non-elemental diet can be used as a probiotic tool to alter the dysbiotic microbiome found in individuals with ulcerative colitis and thereby decrease disease activity.
- Trial name
- NCT04121806
- Testing
- UC intervention diet
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Mount Sinai Hospital, Canada
Colitis, Ulcerative
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic…
- Trial name
- DUET ENCORE-UC (NCT07577856)
- Testing
- JNJ-78934804, Guselkumab
- Where
- 279 sites in United States, Argentina and 30 more
- Volunteers
- 644 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.
This study aims to evaluate the efficacy and safety of acupuncture combined with mesalazine (an integrated acupuncture-medication regimen) for ulcerative colitis.
- Trial name
- NCT07389824
- Testing
- Acupuncture, Mesalazine
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Qin Yu
Ulcerative Colitis, Ulcerative Proctitis
A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis
This will be a phase I/IIa, open-label, three-stage, single center study aimed at investigating the safety, the efficacy (clinical and endoscopic effects) and the pharmacokinetics of Niclosamide enema 150 mg/60 ml and 450 mg/60…
- Conditions
- Ulcerative Colitis, Ulcerative Proctitis, Ulcerative Proctosigmoiditis
- Trial name
- NCT03521232
- Testing
- Niclosamide
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Entero Therapeutics
Distal Ulcerative Colitis
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)
This national, observational and multicentre study aims at establishing a picture of real clinical practices management among patients treated with Pentasa®, according to the current therapeutic strategy in proctitis or distal…
- Trial name
- QUARTZ (NCT02368743)
- Testing
- mesalazine
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Ferring Pharmaceuticals
Moderate to Severe Ulcerative Colitis
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
This study is a multicenter, randomized, double-blind study. There are three dosage groups: Hemay005 45 mg BID group, 60 mg BID group or placebo group, with 36 patients in each dosage group.
- Trial name
- NCT05486104
- Testing
- Hemay005 tablets
- Where
- 18 sites in China
- Volunteers
- 92 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd